- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02646475
Metabolic Effects of Angiotensin-(1-7)
January 30, 2024 updated by: Italo Biaggioni, Vanderbilt University
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity.
Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies.
It is unclear if this peptide contributes to the regulation of metabolism in humans.
The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance.
The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This is an outpatient study that requires a screening visit and two study days in the Vanderbilt Clinical Research Center.
Subjects will be asked to stop taking any medications for high blood pressure for at least 2 weeks prior to the study.
Subjects will receive intravenous angiotensin-(1-7) or saline infusion on two separate study days, with each study day lasting approximately four hours.
There will be at least one week of washout between study days.
On each study day, subjects will be instrumented with two intravenous catheters (one for blood sampling and one for drug infusion), arm and finger blood pressure cuffs, and sticky patches to measure heart rate throughout the study.
The investigators will take baseline measurements of blood pressure and heart rate and collect blood samples.
The investigators will also perform a rebreathing test to measure the heart's pumping capacity.
After baseline measurements, the investigators will infuse angiotensin-(1-7) or saline for 30 minutes, with blood pressure and heart rate measured every 10 minutes.
At the end of 30 minutes, blood samples will be collected and the rebreathing test will be repeated.
The investigators will continue the angiotensin-(1-7) or saline infusion for an additional 2 hours while performing a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity.
Study Type
Interventional
Enrollment (Estimated)
19
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kaleigh Rae, MPH
- Phone Number: 615-875-7421
- Email: kaleigh.rae@vanderbilt.edu
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University School of Medicine
-
Contact:
- Kaleigh Rae, MPH
- Phone Number: 615-875-7421
- Email: kaleigh.rae@vanderbilt.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males and females of all races between 18 and 60 years of age
- Obesity defined as body mass index between 30-40 kg/m2
- Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score >2.2
- Hypertension defined by two or more properly measured seated blood pressure readings >130/85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension.
- Able and willing to provide informed consent
Exclusion Criteria:
- Pregnancy or breast-feeding
- Current smokers or history of heavy smoking (>2 packs/day)
- History of alcohol or drug abuse
- Morbid obesity (BMI > 40 kg/m2)
- Previous allergic reaction to study medications
- Evidence of type I or type II diabetes (i.e. fasting glucose >126 mg/dl, use of anti-diabetic medications)
- Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
- History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
- History or presence of immunological or hematological disorders
- Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) > 2.0 x upper limit of normal range]
- Impaired renal function (serum creatinine >1.5 mg/dl)
- Anemia (hemoglobin <13.5 g/dl in males or <12.5 g/dl in females)
- Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors
- Treatment with phosphodiesterase 5 inhibitors
- Treatment with anticoagulants
- Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
- Treatment with any investigational drug in the 1 month preceding the study
- Inability to give, or withdraw, informed consent
- Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Angiotensin-(1-7)
Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7).
The doses are 4, 8, and 16 ng/kg/min.
Each dose will be maintained for 10 minutes.
The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
|
This is a biologically active endogenous angiotensin peptide.
It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
Other Names:
|
Placebo Comparator: Saline
Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day.
The saline infusion will also be maintained for a total of 150 minutes.
|
Normal saline will be used as a placebo comparator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whole-Body Insulin Sensitivity
Time Frame: steady-state (time 90 to 120 minutes) during hyperinsulinemic-euglycemic clamp
|
Whole-body insulin sensitivity will be defined as the glucose infusion rate needed to maintain euglycemia during steady state (time=90 to 120 minutes) of the hyperinsulinemic-euglycemic clamp following angiotensin-(1-7) versus saline infusion.
The insulin sensitivity will be corrected by body weight, lean body mass, and steady-state plasma insulin concentrations.
|
steady-state (time 90 to 120 minutes) during hyperinsulinemic-euglycemic clamp
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure
Time Frame: 150 minutes
|
The change in blood pressure following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Heart Rate
Time Frame: 150 minutes
|
The change in heart rate following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Cardiac Output
Time Frame: 150 minutes
|
The change in cardiac output following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Stroke Volume
Time Frame: 150 minutes
|
The change in stroke volume following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Systemic Vascular Resistance
Time Frame: 150 minutes
|
The change in systemic vascular resistance following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renin Activity
Time Frame: 150 minutes
|
The change in plasma renin activity following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Angiotensin Peptides
Time Frame: 150 minutes
|
The change in plasma angiotensin peptides following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Aldosterone
Time Frame: 150 minutes
|
The change in plasma aldosterone following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Adipokines
Time Frame: 150 minutes
|
The change in circulating adipokines following angiotensin-(1-7) versus saline infusion.
|
150 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Italo Biaggioni, MD, Vanderbilt University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2016
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
December 31, 2015
First Submitted That Met QC Criteria
December 31, 2015
First Posted (Estimated)
January 5, 2016
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Hyperinsulinism
- Metabolic Syndrome
- Insulin Resistance
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Serine Proteinase Inhibitors
- Vasoconstrictor Agents
- Angiotensin I (1-7)
- Angiotensin II
- Angiotensinogen
Other Study ID Numbers
- 151699
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Angiotensin-(1-7)
-
University of ArizonaNational Heart, Lung, and Blood Institute (NHLBI); Suburban HospitalSuspendedCognitive Impairment | Coronary Artery Bypass SurgeryUnited States
-
Instituto de Cardiologia do Rio Grande do SulUnknown
-
Amy ArnoldAmerican Heart AssociationRecruiting
-
Milton S. Hershey Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Amy ArnoldRecruiting
-
University of ArizonaUnited States Department of DefenseNot yet recruiting
-
Rambam Health Care CampusConstant Therapeutics LLCRecruiting
-
US Biotest, Inc.Tarix PharmaceuticalsTerminatedHIV InfectionsUnited States
-
Erasme University HospitalFonds Erasme pour la Recherche MedicaleNot yet recruitingRespiratory Failure | SARS-CoV-2 | Coronavirus | Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
-
Erasme University HospitalFederal University of Minas Gerais; Fonds Erasme pour la Recherche Medicale; ...Completed